[{"address1": "2000 Sierra Point Parkway", "address2": "Suite 400", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "415 798 8589", "website": "https://www.tempesttx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.", "fullTimeEmployees": 19, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen R. Brady J.D., LLM", "age": 53, "title": "CEO, President & Director", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 740950, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Samuel  Whiting M.D., Ph.D.", "age": 57, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": 591225, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nicholas  Maestas", "age": 43, "title": "VP of Strategy & Finance and Secretary", "yearBorn": 1980, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Justin  Trojanowski", "age": 35, "title": "Corporate Controller, Treasurer & Principal Accounting Officer", "yearBorn": 1988, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sharon  Sakai Ph.D., RAC", "title": "Head of Regulatory & Quality", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.96, "open": 4.0, "dayLow": 3.83, "dayHigh": 4.0175, "regularMarketPreviousClose": 3.96, "regularMarketOpen": 4.0, "regularMarketDayLow": 3.83, "regularMarketDayHigh": 4.0175, "beta": -2.611, "forwardPE": -3.0542636, "volume": 548582, "regularMarketVolume": 548582, "averageVolume": 2565015, "averageVolume10days": 756960, "averageDailyVolume10Day": 756960, "bidSize": 800, "askSize": 1000, "marketCap": 75835152, "fiftyTwoWeekLow": 0.17, "fiftyTwoWeekHigh": 9.77, "fiftyDayAverage": 3.8594, "twoHundredDayAverage": 2.263565, "currency": "USD", "enterpriseValue": 85723128, "floatShares": 14817684, "sharesOutstanding": 19247500, "sharesShort": 463348, "sharesShortPriorMonth": 638636, "sharesShortPreviousMonthDate": 1701302400, "dateShortInterest": 1703808000, "sharesPercentSharesOut": 0.0241, "heldPercentInsiders": 0.03642, "heldPercentInstitutions": 0.40108, "shortRatio": 0.34, "shortPercentOfFloat": 0.031400003, "impliedSharesOutstanding": 19247500, "bookValue": -0.083, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -31106000, "trailingEps": -2.2, "forwardEps": -1.29, "lastSplitFactor": "1:15", "lastSplitDate": 1624838400, "enterpriseToEbitda": -2.851, "52WeekChange": 0.9701493, "SandP52WeekChange": 0.19902325, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TPST", "underlyingSymbol": "TPST", "shortName": "Tempest Therapeutics, Inc.", "longName": "Tempest Therapeutics, Inc.", "firstTradeDateEpochUtc": 1352730600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d54d822e-cd83-39cb-b46d-5c9b6edb9502", "messageBoardId": "finmb_552715229", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.94, "targetHighPrice": 47.0, "targetLowPrice": 8.0, "targetMeanPrice": 21.67, "targetMedianPrice": 10.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 11118000, "totalCashPerShare": 0.578, "ebitda": -30064000, "totalDebt": 21006000, "quickRatio": 1.498, "currentRatio": 1.656, "returnOnAssets": -0.43853, "returnOnEquity": -2.43177, "freeCashflow": -17403624, "operatingCashflow": -27661000, "financialCurrency": "USD", "trailingPegRatio": null}]